Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093848 | 0.87 | NPC1 (0.59) | HSP90AA1NPC1RAB9AADORA3MEN1 | |
| SCHEMBL3099110 | 0.85 | KCNH2 (0.53) | HSP90AA1NPC1RAB9AADORA3POLB | |
| SCHEMBL3093712 | 0.81 | HSP90AA1 (0.51) | HSP90AA1ADORA3MEN1KMT2AADORA2A | |
| SCHEMBL3075309 | 0.78 | NPC1 (0.56) | HSP90AA1NPC1RAB9AADORA3POLB | |
| SCHEMBL3089779 | 0.75 | ADORA3 (0.56) | NPC1RAB9AADORA3POLBADORA2A | |
| SCHEMBL3075306 | 0.72 | MEN1 (0.54) | HSP90AA1MEN1KMT2ALMNA | |
| SCHEMBL3099398 | 0.72 | ADORA3 (0.65) | HSP90AA1ADORA3ADORA2AADORA1TP53 | |
| SCHEMBL17914162 | 0.71 | ATM (0.66) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL13144416 | 0.70 | CYP3A4 (0.52) | HSP90AA1NPC1RAB9AADORA3MEN1 | |
| SCHEMBL31396772 | 0.70 | NPC1 (0.69) | NPC1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NPC1 1106/4885RAB9A 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.